1080.8000 -47.40 (-4.20%)
NSE Jul 08, 2026 15:31 PM
Volume: 109.5K
 

1080.80
-4.20%
Geojit BNP Paribas
The company reiterated its FY28 revenue target of $400 million, supported by a pipeline of 60+ pending low-competition U.S. product launches. Management also remains optimistic about other regulated markets, where portfolio expansion and new customer additions are expected to drive stronger growth and gradually scale revenues to levels comparable to the U.S. business....
Geojit BNP Paribas increased Buy price target of Strides Pharma Science Ltd. to 1352.0 on 02 Jul, 2026.
More from Strides Pharma Science Ltd.
Recommended